SANUWAVE HEALTH REPORTS THIRD QUARTER 2019

SANUWAVE HEALTH REPORTS THIRD QUARTER 2019 FINANCIAL

EXPECTS FOURTH QUARTER REVENUE TO EXCEED ONE MILLION

SUWANEE, GA, November 15, 2019 - SANUWAVE Health,

Inc. (OTCQB: SNWV) reported financial results for the three and

nine months ended September 30, 2019 with the SEC on Thursday,

November 14, 2019. The Company will also host a conference call

today, November 15, 2019, at 9:00 a.m. Eastern

Highlights from the third quarter and last few weeks:

Q4 revenue to exceed $1million, due to the Brazil deal, Strong

International orders, and domestic procedural revenue

Placed 58 dermaPACE Systems

in the United States in total by the end of the third quarter and

have achieved 70 placed by the end of October. On track to reach 85

by end of November and 110 by year end. We plan to place at least

abstracts, symposium, and posters at four conferences in third

quarter; DFCon, SAWC, AAWC Sacramento and Wounds Canada. Our global

partners also participated in three conferences.

200 patients treated and over 1,500 treatments

200 clinicians certified to use and treat with dermaPACE

completion of Medical Device Single Audit Program (MDSAP) and

Korean Ministry of Food and Drug Safety (MFDS).

at Global Diabetic Foot Course (GDFC) in Muscat, Oman with our

partners in the region, Taiba Healthcare and MenaCare.

of a term sheet for a Brazilian joint venture for the dermaPACE

System with IDIC Group of S o Paulo, Brazil. Fees for

partnership are $600,000 with cash payments already

of a distribution partnership agreement with Ametus Group for the

commercialization of the dermaPACE System.

SANUWAVE's focus during 2019 remains placing devices

with qualified clinicians in fifteen target states. We have added

some significant talent in 2019 with new employees joining us from

very well established wound companies and medical backgrounds. The

buzz around our device and product is growing through our expanded

presence at tradeshows, addition of new hires, published articles,

increased social media footprint, but most importantly through word

of mouth from professionals to each other about how great and

successful the device is in treating DFU's. Third quarter was

one of our busier quarters on record for activity and the team

performed extremely well. We also began to refine our processes

from learnings in the field. The refinement in implementation and

support and sales cycles will help improve our efficiency and

customer interactions as we move forward. Through these process

improvements we are comfortable that we will achieve our placement

goals for 2019. Added to this comfort is the recently announced

agreement with Ametus Group to help support and accelerate our

growth in 2019, 2020 and beyond. The playbook we are following is

the same playbook used by many successful medical device companies.

The fourth quarter will begin the revenue trends from all the hard

work as we begin recognizing revenue from these placements. We are

confident we will exceed one million dollars in revenue in the

fourth quarter driven by Brazil, other international partners and

dermaPACE procedural revenue. We are still working with our

auditing firm to determine how much of the initial procedural

revenue will be recognized in Q4, and we will discuss this more on

the year end call, stated Kevin Richardson,

SANUWAVE President, Shri Parikh added, The 300

qualified customer leads from the past four wound care conferences

and ongoing payments of reimbursement claims activity continue to

validate the cost efficiency of

SANUWAVE's dermaPACE technology on the treatment of DFUs and

the cost avoidance of amputation. Commercializing this only FDA

cleared shockwave technology, with our new and growing sales and

clinical professionals experienced in wound care together with

clinicians that are deeply committed to driving positive change in

today's healthcare ecosystem is highly

Goals for 2019 and update on progress

dermaPACE system placements and 300 certified users

at end of Q3, 85 by end of November, and 110 by year

certified users on track for over 300 by year end

with at least 10 million covered lives for insurance

2-3 domestic clinical studies. On track with 2 perfusion studies

and dosage study under way

3-4 new countries. On track to exceed this goal.

additional advisors to our scientific board. On track for additions

other key senior management positions. Continuous process with

This year sets the stage for SANUWAVE to shift from a clinical

research company to a rapidly growing commercialization

company. The process involves placing devices, training

clinicians, gaining reimbursement, and supporting the

infrastructure with more clinical research, published articles, and

case studies. The method will allow SANUWAVE to achieve the

goal of delivering a dermaPACE System anywhere and everywhere a DFU

is treated. This allows SANUWAVE to accomplish the vision of

providing a positive impact on life and the environment, one shock

We are well on our way of achieving our stated goals for 2019 which

will allow for rapid revenue growth in 2020 and beyond. Our stated

long term goal is to reach 2,000 placed devices and $100 million in

Revenue in three to four years. To accomplish this long term goal,

we establish yearly goals and objectives by which investors can

measure managements performance. 2019 is on track to meet or exceed

our objectives for the year. SANUWAVE will release their goals for

2020 in early 2020, but plan to have at least 300 devices placed

during 2020 as part of those goals.

Third Quarter Financial Results

for the three months ended September 30, 2019 were $197,640,

compared to $595,789 for the same period in 2018, a decrease of

$398,149, or 67%. Revenue resulted primarily from sales in Europe

and Asia/Pacific of our orthoPACE devices and related applicators.

The decrease in revenue for 2019 was primarily due to a return of

sales of devices and applicators as a result of the termination of